What Your GP Might Not Tell You About Your Blood Test Results

You’ve had your blood drawn, waited a few days, and received the reassuring message from your GP: "Everything looks normal." You breathe a sigh of relief and carry on with life. But here’s the question most people never think to ask — what does "normal" actually mean, and is it the same as "optimal"?

The reality is that standard pathology reference ranges are designed to identify disease, not to optimise health. They represent the statistical spread of results from the general population — a population that includes people with undiagnosed conditions, poor lifestyle habits, and subclinical dysfunction. Being "within range" simply means you don’t have a flagged abnormality. It does not mean your biomarkers are where they should be for peak health and longevity.

The Problem with Reference Ranges

Pathology reference ranges are typically set at the 2.5th to 97.5th percentile of a tested population. This means that 95% of people will fall within the "normal" range by definition — regardless of their actual health status. Consider thyroid-stimulating hormone (TSH) as an example. The standard Australian reference range for TSH is approximately 0.4 to 4.0 mIU/L. However, research suggests that optimal thyroid function is associated with a TSH closer to 1.0–2.0 mIU/L (Wartofsky & Dickey, 2005). A TSH of 3.8 would be reported as "normal," yet many patients at this level experience symptoms of subclinical hypothyroidism including fatigue, weight gain, and brain fog.

The same principle applies across numerous biomarkers. Fasting glucose levels up to 5.9 mmol/L are considered normal, yet research from the New England Journal of Medicine has demonstrated that cardiovascular risk begins to increase at levels above 5.0 mmol/L (Selvin et al., 2010). By the time you reach 5.9, metabolic dysfunction may have been developing for years.

What GPs Are Trained to Do

It’s important to understand that this isn’t a criticism of general practitioners. Australian GPs are highly trained professionals who operate within a system designed for acute care and disease management. In a standard 15-minute consultation, the priority is identifying and treating pathology — not fine-tuning biomarker optimisation. Medicare-funded consultations are structured around clinical necessity, which means that unless your results indicate a diagnosable condition, there is often limited time or incentive to discuss borderline values in detail.

Furthermore, GPs rely on pathology lab reports that use binary flagging systems: either a result is within range (no flag) or outside it (flagged as high or low). There is no built-in mechanism for highlighting results that are technically normal but trending in the wrong direction. This is where longitudinal tracking becomes invaluable.

The Power of Trends Over Snapshots

A single blood test is a snapshot in time. While it provides useful information, its true power emerges when compared to previous results. For instance, a ferritin level of 180 µg/L is well within the standard male reference range of 30–500 µg/L. But if your ferritin was 80 µg/L two years ago and 130 µg/L last year, that upward trend could signal developing iron overload or chronic inflammation — long before it reaches a level your GP would flag as concerning.

A landmark study in the Annals of Internal Medicine demonstrated that tracking biomarker trajectories over time was significantly more predictive of future disease than any single measurement (Vasan et al., 2004). This is precisely the approach that platforms like Yearly are built around.

Key Biomarkers Where "Normal" May Not Be Enough

Several commonly tested biomarkers have wide reference ranges that can mask early dysfunction:

• Vitamin D: The standard range starts at 50 nmol/L, but mounting evidence suggests that levels between 75 and 125 nmol/L are associated with better immune function, bone health, and mood regulation (Holick, 2007).
• Iron/Ferritin: While ranges extend up to 300–500 µg/L for men, levels above 200 µg/L may warrant investigation for inflammation or early haemochromatosis.
• HbA1c: A result of 5.6% is technically normal but sits at the upper edge, suggesting early insulin resistance that could benefit from dietary intervention.
• Total testosterone: Reference ranges for men start as low as 8 nmol/L, yet symptomatic low testosterone is common below 15 nmol/L.
• Liver enzymes (ALT, GGT): Even within-range elevations of GGT have been associated with increased metabolic and cardiovascular risk in large cohort studies.

What You Can Do

Becoming an informed advocate for your own health doesn’t mean dismissing your GP’s expertise — it means complementing it with deeper analysis. Here are practical steps you can take:

• Request a copy of your full results: Don’t settle for a verbal summary. Ask for the complete pathology report so you can review the numbers yourself.
• Track your results over time: Use a platform like Yearly to upload your blood test PDFs and build a longitudinal record of your biomarkers. Our AI analysis highlights trends and flags results that may be technically normal but worth attention.
• Ask about optimal ranges: When reviewing results with your GP, ask specifically whether your levels are optimal, not just normal.
• Consider additional tests: Some of the most informative biomarkers — such as fasting insulin, ApoB, and hs-CRP — are not included in standard panels. You may need to request them specifically.

The Yearly Difference

At Yearly, we analyse your blood test results through the lens of optimal health, not just disease absence. Our platform uses AI to compare your results against evidence-based optimal ranges, track trends across multiple tests, and provide personalised insights that go far beyond a standard pathology report. Because when it comes to your health, "normal" should never be the ceiling — it should be the floor.

References

1. Wartofsky, L. & Dickey, R.A. (2005). "The Evidence for a Narrower Thyrotropin Reference Range Is Compelling." The Journal of Clinical Endocrinology & Metabolism, 90(9), 5483–5488.
2. Selvin, E., et al. (2010). "Glycated Haemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults." New England Journal of Medicine, 362(9), 800–811.
3. Vasan, R.S., et al. (2004). "Assessment of Risk Factors and Biomarkers Associated with Risk of Cardiovascular Disease Among Women." Annals of Internal Medicine, 140(12), 945–955.
4. Holick, M.F. (2007). "Vitamin D Deficiency." New England Journal of Medicine, 357(3), 266–281.